Rna Diagnostics was awarded first place in the RESI Innovation Challenge held in Boston, Massachusetts on September 16, 2015. The RESI Investor conference included an Innovation Challenge featuring 30 of the most innovative early stage life science companies selected from over 250 biotech, medtech and healthcare IT entrepreneurs.

The Redefining Early Stage Investments (RESI) conference is sponsored by Life Science Nation, a premier provider of Life Science investment information. The conference featured over 250 biotech, medtech and healthcare IT entrepreneurs interacting with 200 investors.  Thirty of the most innovative early stage life science companies, including Rna Diagnostics, were chosen to participate in a virtual investment contest showcasing cutting-edge life science technologies. Rna Diagnostics received the most virtual investment dollars leading to a first place finish in the contest.

Rna Diagnostics is a Canadian cancer diagnostics company developing diagnostic tools to improve chemotherapy management. The company’s first product, RDA™ (RNA Disruption Assay), evaluates early in a woman’s breast cancer treatment how she is responding to chemotherapy.

“This was a great opportunity to present Rna Diagnostics’ strategy and technology to 200 expert life sciences investors and they clearly responded,” said John Connolly, VP Corporate Development of Rna Diagnostics.  “This response to the RDA technology by life science experts is more compelling external recognition.”

Dr. Ken Pritzker, CEO of Rna Diagnostics said, “This reflects the response we’ve seen when sharing the RDA story. This is a cancer diagnostic test that will assist physicians with treatment decisions, save healthcare systems money and most of all, provide information that could make outcomes better for women with breast cancer.”

About Rna Diagnostics Inc.
Rna Diagnostics, a Canadian cancer diagnostics company, is developing diagnostic tools to improve chemotherapy management. The company’s first product, RNA Disruption Assay™ (RDA™), evaluates early in a woman’s breast cancer treatment how she is responding to chemotherapy. If the chemotherapy is not working effectively she can be switched quickly to other treatments, avoiding the harmful side-effects of ineffective chemotherapy, thereby improving her outcome.  Rna Diagnostics is conducting clinical trials and collaborations with leaders in breast cancer research in Germany, Italy, Sweden, Switzerland, United States, United Kingdom and Canada.

For more information on Rna Diagnostics Inc., please contact jconnolly@rnadiagnostics.com
www.rnadiagnostics.com